Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price?

Feb 18 (Reuters) - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ...

Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a ...

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

By Rishika Sadam and Kashish Tandon HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for ...

Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping ...

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

By Padmanabhan Ananthan and Sriparna Roy Feb 9 (Reuters) - Eli Lilly will buy Orna Therapeutics for up to $2.4 billion in ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...